查詢結果分析
來源資料
相關文獻
- 子宮內膜癌的“三明治”式療法
- 以Bevacizumab治療子宮內膜癌的檢視
- 從西醫觀點論婦科腫瘤
- 接受手術以及手術後放射線治療的子宮內膜癌預後的分析
- 一位鼻咽癌病患放射線合併化學治療之護理經驗
- 放射線及化學治癌藥物保護劑
- 早期子宮內膜癌的治療與預後因子
- Treatment of a Pineal Yolk Sac Tumor: Report of One Case
- Concurrent Chemoradiation with Weekly Cisplatin Plus Systemic Adjuvant Chemotherapy for Locally Advanced Esophageal Cancer--A Pilot Study
- 補氣藥對於化學或放射線治療後病人免疫力之作用
頁籤選單縮合
| 題 名 | 以Bevacizumab治療子宮內膜癌的檢視=The Role of Bevacizumab in Endometrial Cancer |
|---|---|
| 作 者 | 李耀泰; 陳福民; 郭宗正; | 書刊名 | 婦癌醫學期刊 |
| 卷 期 | 46 2017.10[民106.10] |
| 頁 次 | 頁19-22 |
| 分類號 | 417.2832 |
| 關鍵詞 | 化學治療; 子宮內膜癌; 放射線治療; Bevacizumab; Chemotherapy; Endometrial cancer; Radiation therapy; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 子宮內膜癌的發生率和死亡率均有增加的趨勢,晚期及復發性子宮內膜癌患者必定跟著增加,治療此類病患成為重要的課題。根據統計顯示,手術外加採骨盆腔放射線治療可減少局部病灶的復發,加用化學治療則可降低遠端轉移。另外,在子宮內膜癌的腫瘤細胞內,血管內皮層生長因子和微血管密度增加越多,則預後越差。Bevacizumab (Avastin 癌思停)乃一種抗血管生長因子藥物,被證實能抑制子宮內膜癌細胞的生長,可單獨或合併化學藥物、放射線來治療子宮內膜癌。但需更多的研究,才知理想的劑量和使用時間的長短。 |
| 英文摘要 | Death rates for endometrial cancer have increased rapidly. Therfore, it is essential to develop effective new methods for the treatment of patients with advanced or recurrent endometrial cancer. Prior studies have indicated that pelvic radiation therapy may decrease the risk of local recurrence, while chemotherapy may reduce the risk of distant metastasis. Increased levels of vascular endothelial growth factor and microvessel density are associated with poor outcome of patients with endometrial cancer. Evidence showed that the addition of bevacizumab, an antiangiogenic agent, may further reduce the risk of local and metastatic lesions. Future regimen will be needed to increase response rates and decrease toxicity. |
本系統中英文摘要資訊取自各篇刊載內容。